Liraglutide InjectionInjection
Weight Loss & GLP-1 Agonists

Liraglutide Injection

Liraglutide

Pioneer once-daily GLP-1 receptor agonist with a 13-hour half-life, approved both as Victoza (1.2-1.8mg for type 2 diabetes) and Saxenda (3.0mg for chronic weight management), with landmark LEADER trial data demonstrating significant cardiovascular mortality reduction. Supplied in 3ml pre-filled pens by Novo Nordisk-aligned and Indian manufacturers and exported globally for endocrinology and specialized weight management clinics.

Strengths

6mg/ml

Packing

1 pre-filled pen (3ml)

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Liraglutide 6mg/ml solution for injection (3ml pre-filled pen)
Dosage Form
Injection
Available Strengths
6mg/ml
Packing
1 pre-filled pen (3ml)
Route of Administration
Subcutaneous injection, once daily
Dosage
Diabetes: start 0.6mg daily, increase to 1.2mg, max 1.8mg; Weight: escalate to 3.0mg daily
Indications
Type 2 diabetes mellitus, chronic weight management in adults with obesity/overweight
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 2-8°C before use; in-use at room temperature up to 30°C for 30 days
Shelf Life
24 months
Side Effects
Nausea, diarrhea, vomiting, constipation, headache, decreased appetite, hypoglycemia
Precautions
Black box: thyroid C-cell tumors; pancreatitis risk; renal impairment monitoring; not for type 1 diabetes; avoid in MEN 2

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Retatrutide InjectionInjection

Retatrutide Injection

Retatrutide

Investigational triple incretin receptor agonist (GIP/GLP-1/Glucagon) demonstrating exceptional weight loss exceeding 24% body weight in Phase 2 trials, surpassing all currently approved anti-obesity medications and representing the next generation of metabolic therapies. Supplied by Indian manufacturers for research procurement and supplied to markets where investigational compounds are accessible under physician oversight.

5mg / 10mg / 20mg
Tirzepatide InjectionInjection

Tirzepatide Injection

Tirzepatide

First-in-class dual GIP/GLP-1 receptor agonist (twincretin) demonstrating superior HbA1c reduction and up to 22.5% body weight loss in SURPASS and SURMOUNT trials, outperforming semaglutide across all dose levels in head-to-head studies. Available in six escalating weekly dose strengths as a single-dose auto-injector pen, supplied by Eli Lilly-aligned and Indian generic manufacturers for diabetes and obesity management globally.

2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg
Semaglutide TabletsTablet

Semaglutide Tablets

Semaglutide

World's first oral GLP-1 receptor agonist (Rybelsus) utilizing SNAC absorption technology to enable gastrointestinal uptake of this large peptide molecule, providing once-daily tablet convenience for type 2 diabetes management with HbA1c reductions comparable to injectable GLP-1 agonists. Supplied in 30-tablet bottles from Novo Nordisk-aligned and Indian manufacturers and exported for diabetes management programs preferring non-injectable therapy.

3mg / 7mg / 14mg

Need bulk pricing for Liraglutide Injection?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote